Skip to main content
. 2018 Nov 27;20(3):261–271. doi: 10.1080/15384047.2018.1529091

Figure 1.

Figure 1.

Expression of lncRNA-TATDN1 in DDP-sensitive or tolerant NSCLC tumor tissues and cell lines and the prognosis of patients after DDP-treatment. (A) qRT-PCR ananlysis of TATDN1 expression in normal tissues and DDP-sensitive or DDP-tolerant NSCLC tumor tissues. (B) TATDN1 expression profile was evaluated by immunohistochemical staining. (C) A total of 88 patients received DDP chemotherapy, followed by the statistics of survival rate in high and low TATDN1 expression groups. (D and E) TATDN1 levels in 16HBE cells and DDP-sensitive or DDP-resistant cell lines were performed by qRT-PCR. *P < 0.05.